ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA)

Historical Holders from Q1 2014 to Q3 2025

Symbol
ENTA on Nasdaq
Type / Class
Equity / Common Stock, par value $0.01 per share
Shares outstanding
27.8M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
19M
Holdings value
$227M
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
119
Number of buys
56
Number of sells
-52
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 12.1% $41.8M 3.49M JANUS HENDERSON GROUP PLC 31 Oct 2025
Farallon Capital Partners, L.P. 9.9% $12M 2.11M Dapice Joshua J. 31 Dec 2024
Luly Jay R. 7.7% $9.66M 1.7M Jay R. Luly, Ph.D. 12 Feb 2025
BlackRock, Inc. 7.8% $9.49M 1.67M BlackRock, Inc. 31 Mar 2025
Deep Track Capital, LP 5.33% $17.8M 1.48M Deep Track Capital, LP 02 Oct 2025
INTEGRATED CORE STRATEGIES (US) LLC 4.1% -34.3% $13.6M -$2.92M 1.14M -17.6% Millennium Management LLC 30 Sep 2025

Institutional Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 19M $227M +$9.08M $11.97 119
2025 Q2 18.4M $139M -$1.13M $7.56 103
2025 Q1 18.6M $103M -$7.31M $5.52 108
2024 Q4 19.9M $114M -$17.7M $5.75 105
2024 Q3 21.2M $220M -$10.2M $10.36 110
2024 Q2 22.1M $287M -$4.64M $12.97 99
2024 Q1 22.4M $391M +$45.3M $17.46 105
2023 Q4 20M $188M -$5.17M $9.41 103
2023 Q3 20.1M $225M -$8.7M $11.17 129
2023 Q2 19.9M $427M -$15.8M $21.40 129
2023 Q1 19.8M $802M +$23.7M $40.44 142
2022 Q4 19.2M $895M -$44.7M $46.52 145
2022 Q3 19.7M $1.02B -$26.6M $51.87 155
2022 Q2 20.2M $956M +$17.3M $47.27 149
2022 Q1 19.7M $1.4B +$60.7M $71.18 163
2021 Q4 18.8M $1.4B -$51.4M $74.78 172
2021 Q3 19.4M $1.1B +$34.6M $56.81 140
2021 Q2 18.8M $829M -$26.9M $44.01 147
2021 Q1 19.4M $957M +$7.4M $49.32 146
2020 Q4 19.3M $811M +$16.3M $42.10 148
2020 Q3 18.9M $863M +$27.2M $45.78 170
2020 Q2 18.3M $917M +$10.5M $50.21 173
2020 Q1 18M $928M -$32.7M $51.43 154
2019 Q4 18.4M $1.14B +$22M $61.78 166
2019 Q3 17.9M $1.08B +$8.73M $60.08 172
2019 Q2 17.7M $1.49B -$2.59M $84.38 192
2019 Q1 17.8M $1.7B +$95.4M $95.52 195
2018 Q4 16.8M $1.19B +$7.02M $70.83 179
2018 Q3 16.6M $1.42B +$118M $85.46 193
2018 Q2 15.1M $1.75B +$46.8M $115.90 188
2018 Q1 14.7M $1.19B +$63M $80.91 177
2017 Q4 14M $822M +$75.2M $58.68 139
2017 Q3 12.8M $598M +$18.4M $46.80 122
2017 Q2 12.6M $454M -$5.7M $35.98 118
2017 Q1 12.8M $396M +$44.3M $30.80 123
2016 Q4 13.3M $447M +$14.3M $33.50 146
2016 Q3 13.1M $349M +$838K $26.61 133
2016 Q2 13.4M $296M -$1.39M $22.05 126
2016 Q1 14.2M $418M -$10.1M $29.37 150
2015 Q4 14.6M $483M -$20.7M $33.02 132
2015 Q3 14.9M $540M +$48.6M $36.14 141
2015 Q2 13.8M $621M +$81.2M $44.99 129
2015 Q1 12.3M $378M +$43.1M $30.62 115
2014 Q4 10.4M $531M +$20.8M $50.85 122
2014 Q3 10M $396M +$13.4M $39.57 109
2014 Q2 9.67M $416M +$53.1M $43.07 97
2014 Q1 8.44M $337M +$158M $39.99 79